Navigation Links
Masimo Reports Third Quarter 2008 Financial Results
Date:10/27/2008

December 29, September 27,

2007 2008

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents $96,733 $122,603

Accounts receivable, net of allowance

for doubtful accounts 26,970 29,511

Royalties receivable 13,866 11,375

Inventories 23,110 29,261

Prepaid expenses 7,084 7,998

Deferred tax assets 14,334 14,334

Other current assets 1,543 873

Total current assets 183,640 215,955

Deferred cost of goods sold 26,249 27,031

Property and equipment, net 11,164 12,816

Deferred tax assets 5,332 5,332

Intangible assets, net 5,589 7,289

Other assets 3,537 2,809

Total assets $235,511 $271,232

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities

Accounts payable $14,640 $14,510

Accrued compensation 12,409 13,404

Accrued liabilities 6,394 6,105

Deferred revenue 16,827 18,606

Current portion of long-term debt 11,539 548

Total current liabilities 61,809 53,173

Long-te
'/>"/>

SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
2. Five New Clinical Studies Show Value of Masimo PVI & PI
3. Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
4. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
5. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
6. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
7. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
8. Masimo Reports First Quarter 2008 Financial Results
9. Atom Medical Adopts Masimo Rainbow SET Technology
10. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
11. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... U.S. Department of Energys Brookhaven National Laboratory have developed ... and micrometer-sized particles. The method, based on designed DNA ... to manipulate the structure and therefore the properties ... be of interest to industry. For example, such fine-tuning ...
... 12 BioReliance Corporation, a,leading contract services ... contracted with Gentronix to offer their,GreenScreen HC ... of BioReliance,s portfolio of,genotoxicity screening services. GreenScreen ... pharmaceutical companies to test for genotoxic potential,earlier ...
... Inc. (Nasdaq:,PPDI) today announced Daniel G. Darazsdi has ... position on October 1. Mr. Darazsdi, 47, ... a $34 billion diversified technology and manufacturing,leader, where ... CFO of finance,transformation and operations. Over the years ...
Cached Biology Technology:New DNA-based technique for assembly of nano- and micro-sized particles 2BioReliance Launches Next-Generation Genotoxicity Screening Service 2PPD Names Daniel Darazsdi as Chief Financial Officer 2PPD Names Daniel Darazsdi as Chief Financial Officer 3
(Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
(Date:7/9/2014)... may be on the verge of an economy driven by ... than coal and is undergoing a production boom. It has ... recent research is casting serious doubts over just how climate-friendly ... Engineering News (C&EN), the weekly news magazine of the ... senior correspondent at C&EN, explains that when burned as a ...
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... span of a common rat, the 10 to 30 year ... to East Africa, is impressive. And compared to the human ... to aging, maintaining high activity, bone health, reproductive capacity, and ... in Israel and the United States is working to uncover ...
... during pregnancy are uncommon, but the prevalence of heart disease ... more women delay pregnancy until they are older. These women, ... tend to have higher cholesterol levels and are at greater ... research has shown that the heart typically functions better during ...
... summer season is in full swing, many of us will be ... have some unwanted guests in the form of mosquitoes. Mosquitoes ... Syed, a mosquito biologist with the University of Notre Dame,s Eck ... determining how they do it. In short, it,s because of ...
Cached Biology News:Naked mole rat may hold the secret to long life 2UCLA study looks at why heart attacks cause so much more damage in late pregnancy 2Mosquitoes -- how we smell is why they bite, research shows 2
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... Costar strip ejector is a unique product ... strips from their holder. Linkage: This CLS ... to easily match Cornings product number. If ... the old Sigma-Aldrich number (Z71,314-7) or contact ...
... hood ventilates and purifies hazardous chemical ... exhaust. Bonded charcoal filters remove most ... clearance (with access shield open) accommodates ... options include final HEPA filter, work ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: